SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-095472
Filing Date
2024-04-15
Accepted
2024-04-15 06:46:02
Documents
13
Period of Report
2024-04-15
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d805556d8k.htm   iXBRL 8-K 22067
  Complete submission text file 0001193125-24-095472.txt   147333

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nmra-20240415.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20240415_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20240415_pre.xml EX-101.PRE 11711
16 EXTRACTED XBRL INSTANCE DOCUMENT d805556d8k_htm.xml XML 3769
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 24843071
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)